Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Doximity surpasses Q4 revenue expectations and eyes continued growth

Doximity's Q4 2023 performance exceeded expectations, showcasing strong financial metrics and strategic investments. The company's outlook for Q1 2024 indicates continued growth, with a focus on topline expansion and product innovation. While facing challenges in pricing strategies and competitive landscape, Doximity is well-positioned to capitalize on opportunities in the healthcare technology sector.

Doximity reports strong Q1 results but lowers 2024 guidance

Doximity delivered strong financial performance in Q1, but challenges in upsell close rates led to a downward revision in annual guidance. The company's focus on innovation, expansion, and shareholder value, along with a cautious outlook for the remainder of the year, presents a mixed picture of opportunities and challenges for investors.

Doximity reports strong Q3 earnings, eyes growth amid product challenges

Doximity's Q3 performance demonstrated resilience and growth potential despite challenges in meeting annual guidance due to product delays.
The company's focus on innovation, strong client relationships, and strategic investments position it well for future growth and market leadership.
With a commitment to R&D, expanding product offerings, and maintaining pricing discipline, Doximity aims to capitalize on opportunities and navigate challenges for sustained success.

Doximity surpasses Q4 revenue targets, poised for growth and innovation

Doximity's Q4 performance exceeded expectations, with robust revenue growth, strong margins, and strategic investments in new products and talent.
While facing challenges like flat growth in certain segments and pricing adjustments, the company is well-positioned to capitalize on opportunities in network expansion and technology innovation.
With a focus on enhancing user experience, driving engagement, and optimizing revenue streams, Doximity is poised for continued success and value creation for shareholders.
The company's financial health, innovative product offerings, and market positioning indicate a promising outlook for sustained growth and competitive advantage in the healthcare technology sector.

Doximity surpasses Q1 revenue expectations, faces upsell challenges

Doximity's Q1 performance was strong, but challenges in upsells prompted a staff reduction and revised guidance. The company is optimistic about long-term growth, leveraging new products and a self-serve ad platform for future success.

Doximity beats Q2 expectations, eyes growth amidst market uncertainties

Doximity's strong Q2 performance exceeded revenue and EBITDA guidance, driven by record physician engagement and new product success.
While facing market uncertainties and competition challenges, the company sees opportunities in pricing strategies and continued growth.
Investments in high-touch services, Telehealth, and video products are paying off, with a focus on enhancing client offerings.
Integration with IQVIA for real-time ROI analysis positions Doximity for future growth and client value creation.

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) (“Doximity” or the “Company”) on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action, captioned Kissler v. Doximity, Inc., et al., Case No. 3:24-cv-02281-JST was filed in the United States District Court for the Northern District of California. Important Deadline Reminder: Investors who purchased or otherwise acquired Doximity common stock during the Class Period may, no later than June 17, 2024, move the Court to serve as lead plaintiff for the class.

NYSE: DOCS: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Doximity, Inc.

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.

CRUCIAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.

IMPORTANT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm

NEW ORLEANS , May 31, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District California.

DOXIMITY SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS

RADNOR, Pa. , May 31, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").

Class Action Announcement for Doximity, Inc. (DOCS): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Doximity, Inc.

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm

NEW YORK , May 30, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 17, 2024 lead plaintiff deadline . SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5, 2024 at 2:00 p.m. Central Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties.

Doximity to Present at the William Blair 44th Annual Growth Stock Conference

RADNOR, PA / ACCESSWIRE / May 30, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE:DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"). This action, captioned Kissler v.

NYSE: DOCS: Kessler Topaz Meltzer & Check, LLP Files a Securities Class Action Lawsuit Against Doximity, Inc.

LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm

Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Doximity (DOCS) Upgraded to Buy: Here's What You Should Know

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) (“Doximity” or the “Company”) on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action, captioned Kissler v. Doximity, Inc., et al., Case No. 3:24-cv-02281-JST was filed in the United States Di.

NYSE: DOCS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Doximity, Inc.

LOS ANGELES , May 24, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its 2024 Physician Compensation Report. The report reveals that the average pay for doctors increased 5.9% in 2023 after a decline of 2.4% the previous year. The report also points to a 23% gender wage gap, with men physicians earning nearly $102,000 more than women physicians, even when controlling for specialty, location, and years of experience. The report.

Doximity Releases New Study on Physician Compensation, Overwork, and Shortage

New York , May 22, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 17, 2024 lead plaintiff deadline . SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS

Doximity Inc. NASDAQ: DOCS is a social networking platform exclusively designed for U.S. healthcare professionals. It's a cross between Meta Platforms Inc. NASDAQ: META owned Facebook and Microsoft Co. NASDAQ: MSFT owned LinkedIn.

Doximity is the Facebook and LinkedIn of the Medical Community

NEW YORK--(BUSINESS WIRE)---- $DOCS #DOCS--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 17, 2024 lead plaintiff deadline. SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO D.

DOCS INVESTOR NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS

LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm

Shares in Doximity (DOCS) surged Friday after the digital medical networking company announced earnings that beat Wall Street estimates, provided a better-than-expected current-quarter outlook, and unveiled a share buyback program.

Doximity Surges on Earnings Beat, Strong Outlook, Stock Buyback Announcement

Doximity, Inc. (NYSE:DOCS ) Q4 2024 Earnings Conference Call May 16, 2024 5:00 PM ET Company Participants Perry Gold - Vice President Investor Relations Jeff Tangney - Co-Founder and Chief Executive Officer Anna Bryson - Chief Financial Officer Nate Gross - Co-Founder and Chief Strategy Officer Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham & Company Jared Hass - William Blair Richard Close - Canaccord Genuity Glen Santangelo - Jefferies Elizabeth Anderson - Evercore ISI Dan Clark - Leerink Partners Anne Samuel - JPMorgan Stan Berenshteyn - Wells Fargo Securities Stephanie Davis - Barclays Jack Wallace - Guggenheim Securities Jailendra Singh - Truist Securities Jessica Tassan - Piper Sandler Scott Schoenhaus - KeyBanc Craig Hettenbach - Morgan Stanley Operator Thank you for standing by. My name is Greg and I will be your conference operator today.

Doximity, Inc. (DOCS) Q4 2024 Earnings Call Transcript

Doximity (DOCS) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.20 per share a year ago.

Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 fourth quarter and fiscal year ended March 31, 2024. “We were pleased to beat on our top and bottom lines, as we delivered another quarter of strong profits and record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. “We're proud to bring AI and automation to clinical workflows, with over 580,000 unique providers usin.

Doximity Announces Fourth Quarter and Fiscal Year 2024 Financial Results

NEW YORK , May 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 17, 2024 lead plaintiff deadline . SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS

NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Doximity, Inc (“Doximity” or the “Company”) (NYSE: DOCS) securities during the period of February 9, 2022 through April 1, 2024, inclusive (“the Class Period”). Investors have until June 17, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click h.

Kirby McInerney LLP Reminds Doximity, Inc. (DOCS) Investors of Class Action Filing and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.

News for Doximity Stock (DOCS)